Bracco Imaging S.p.A., a global leader in diagnostic imaging based in Milan, Italy, has marked a significant advancement in its AI and Digital Health strategy with the commercial launch of AiMIFY® across the European Union. This innovative AI-powered software, developed in collaboration with U.S.-based Subtle Medical, Inc., enhances contrast in brain MR images post-injection of gadolinium-based contrast agents (GBCAs). By amplifying existing contrast enhancement, AiMIFY® delivers more detailed post-contrast images, bolstering radiologists' and neuroradiologists' confidence in detecting and assessing brain lesions without altering established imaging protocols or standards of care.

Ajit Shankaranarayanan, PhD, Chief Product Officer at Subtle Medical, emphasized the milestone nature of this EU launch, stating, 'AiMIFY® was designed to maximize diagnostic information from contrast-enhanced MRI while preserving standard of practice.' This technology represents a leap forward in pharmaceutical instrumentation and controls, particularly in MRI workflows, enabling sharper lesion visualization and potentially improving diagnostic accuracy in neurology and oncology applications.

Complementing the AiMIFY® rollout, Bracco announced a strategic co-development and commercial partnership with Avicenna.AI, a frontrunner in medical AI solutions. The collaboration targets computer-aided detection and diagnosis in brain CT angiography using contrast-enhanced computed tomography (CT). Currently under development and clinical validation at select U.S. and European sites, this AI solution aims to accelerate clinical decision-making. FDA submission is slated for the second half of 2026, signaling robust regulatory momentum.

Cyril Di Grandi, Co-founder and CEO of Avicenna.AI, highlighted the synergy: 'We are pleased to partner with Bracco to advance AI-driven computer-aided detection and diagnosis in contrast-enhanced CT.' This partnership leverages Bracco's expertise in contrast imaging and Avicenna.AI's interpretative AI prowess, addressing the growing complexity of imaging data volumes in radiology departments.

Fabio Tedoldi, Head of Global R&D at Bracco Imaging, underscored the company's century-long legacy in diagnostic imaging: 'Our partnership with Avicenna.AI expands our capabilities into AI-driven image interpretation. Together with AiMIFY®, this reflects our strategy to extend support across the imaging workflow—from the scanning room to the reading room.' These initiatives align with broader trends in laboratory automation and robotics and pharmaceutical instrumentation, where AI integration is optimizing operational efficiency and diagnostic precision for pharmaceutical and healthcare tech stakeholders.

Both milestones will be showcased at the 2026 European Congress of Radiology (ECR) through dedicated sessions featuring Bracco and its AI partners. This event provides a prime platform for CRO/CMO leaders, R&D heads, and technology vendors to explore how such innovations impact clinical trial imaging, regulatory compliance, and supply chain logistics in pharma operations.

Bracco Imaging's portfolio extends beyond contrast agents to include X-ray, CT, MRI solutions, microbubbles for Contrast Enhanced Ultrasound (CEUS), and molecular imaging via radioactive tracers and PET agents. With over 3,800 employees supporting operations in more than 100 countries since 1927, Bracco is positioning itself at the forefront of precision medicine. The AiMIFY® launch and Avicenna.AI tie-up exemplify strategic investments in digital health, potentially influencing pharmaceutical outsourcing and validation processes by standardizing AI-enhanced imaging protocols across EU facilities.

For manufacturing managers and procurement professionals, these developments signal opportunities in upgrading imaging infrastructure with AI-compatible systems, ensuring compliance with evolving EU regulations on medical devices and AI software. Regulatory teams will note the seamless integration with existing GBCAs, minimizing validation hurdles. The partnerships also highlight the importance of cross-Atlantic collaborations in accelerating pharmaceutical R&D timelines, fostering innovation in cleanroom-compatible imaging tech and data handling solutions.

In the context of Europe's pharmaceutical landscape, Bracco's moves reinforce Italy's role as a hub for medtech innovation, potentially spurring economic and regional development in the sector. As imaging volumes surge due to aging populations and chronic disease prevalence, AI tools like AiMIFY® and Avicenna.AI's CT solutions promise to streamline workflows, reduce radiologist burnout, and enhance patient pathways—key priorities for pharma executives navigating capacity constraints.

Looking ahead, Bracco's commitment to sharing knowledge and cultivating thought leaders positions it to influence standards in spectroscopy, pharmaceutical quality assurance, and beyond. Stakeholders in contract research organizations (CROs) and contract manufacturing organizations (CMOs) stand to benefit from these tools in trial endpoints involving neuroimaging, where precise lesion detection is paramount. This announcement not only expands Bracco's AI portfolio but also sets a benchmark for B2B partnerships driving tangible operational gains in the pharmaceutical tech ecosystem.